Login to Your Account


LONDON – Mina Therapeutics Ltd. is laying claim to be first in the clinic with a novel RNA therapeutic that, in contrast to its more established siRNA gene silencing counterparts, activates dormant genes.

After years of taking a back seat to research efforts in indications such as cardiovascular disease, cancer and pulmonary disease, the gastrointestinal space is hot.

Having worked in academia, big pharma and venture capital, Naia Ltd. co-founder H. Daniel Perez got to witness drug development from three different perspectives, and he came away with one conclusion: "It was very clear things were not being done efficiently," he said.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: